Bioventus Inc - Ordinary Shares - Class A
BVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$817.04M
Close$
$25.73
124.2% upside
Current Fair Value
124.2% upsideUndervalued by 124.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $817.04 Million |
|---|---|
| Enterprise Value | $799.95 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.34 |
| Beta | 0.65 |
| Outstanding Shares | 67,296,336 |
Return
| Return on Equity | 15.08% |
|---|---|
| Return on Assets | 4.38% |
| Return on Invested Capital | 12.61% |
Valuation & Multiples
| P/E Ratio | 28.48 |
|---|---|
| PEG | -13.06 |
| Price to Sales | 1.44 |
| Price to Book Ratio | 3.83 |
| Enterprise Value to Revenue | 1.39 |
| Enterprise Value to EBIT | 12.63 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$130.32 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$155.64 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 23.77% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.37%▼ 75.50% |
|---|---|
| Total Invested | $2.33M▼ 99.50% |
| Investors Holding | 11▼ 148.00% |
ESG Score
No data
About Bioventus Inc
700 employeesBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioven...